Applied Biosystems to Webcast Presentation at First Analysis Investment Conference.

FOSTER CITY, Calif. -- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, will webcast its presentation at the First Analysis Investment Conference on Thursday, November 17, 2005. The live presentation is scheduled to begin at 2:00 p.m. ET. Peter Dworkin, Vice President of Investor Relations and Corporate Communications for Applera Corporation, will provide an overview of the business with a focus on corporate strategy and examples of recent scientific discoveries enabled by Applied Biosystems' products.

Interested parties may access the live webcast and replay by visiting the Investors section of the Applied Biosystems website at http://ir.appliedbiosystems.com or the Investors & Media section of the Applera website at www.applera.com. It is suggested that participants access the webcast 15 minutes before the start of the live webcast. The webcast replay will be archived on the Presentations page of the Investors section of each website.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800-762-6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.

Copyright(C) 2005. Applera Corporation. All rights reserved. Applied Biosystems is a registered trademark and Applera, Celera, Celera Diagnostics, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.